北京若生智能科技有限公司
Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Mylan研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Abevmy, bevacizumab, Biocon, Krabeva
公司Mylan
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Mylan

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedJournal of neuro-oncology2026-09-10

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.

Loxterkamp Elizabeth E, Luo Audrey A, Sanvito Francesco F, Le Collin T CT et al.

Pretreatment apparent diffusion coefficient (ADC) histogram analysis-specifically the lower Gaussian peak mean (ADC-L)-is a predictive biomarker of progression-free survival (PFS) and overall survival (OS) in recurrent IDH-wildtype glioblastoma receiving anti-VEGF treatment including bevacizumab. IDH-mutant gliomas differ biologically from glioblastoma, as they exhibit lower tumor cellularity, longer survival, and distinct sensitivity to a variety of therapies. Whether ADC-L retains predictive utility in IDH-mutant recurrent glioma has not been established. In this retrospective, single-center study, sixty patients with IDH-mutant recurrent glioma (41 astrocytoma, 19 oligodendroglioma) with measurable contrast enhancement and available pretreatment diffusion-weighted MRI who received bevacizumab were analyzed. Univariate and multivariate Cox regression and Kaplan-Meier analyses were performed for PFS and OS. The optimal ADC-L threshold was 1.19 μm2/ms. High ADC-L (≥1.19 μm2/ms) was associated with significantly longer PFS (median 5.46 vs. 2.76 months; p = 0.006) but not OS. In multivariate analysis, low ADC-L (HR = 2.054; p = 0.0228) and astrocytoma histology (HR = 2.295; p = 0.0158) were independent predictors of shorter PFS when accounting for number of prior recurrences. ADC-L was also significant predictor of PFS in both astrocytoma and oligodendroglioma patients, independently, after accounting for number of recurrences. Pretreatment ADC-L predicts PFS in IDH-mutant recurrent glioma receiving bevacizumab. Supporting prospective evaluation of ADC-L as a biomarker for bevacizumab patient selection in this population.

PMID 42717134
阅读全文 →
PubMedNeuro-oncology advances2026-09-10

[18F]FET PET imaging for early response assessment of bevacizumab in recurrent glioblastoma.

Chiranth Shivani S, Henriksen Otto Mølby OM, Hasselbalch Benedikte B, Grunnet Kirsten K et al.

Bevacizumab combination therapy has shown response in approximately 25% of recurrent glioblastoma (GBM) patients. This study aimed to investigate the value of O-(2-18F-fluoroethyl)-l-tyrosine positron emission tomography ([18F]FET PET) imaging and the relevance of the PET-based response assessment criteria for diffuse gliomas (PET RANO) criteria in assessing response to bevacizumab combination therapy in recurrent GBM. All recurrent GBM IDH-wildtype patients treated with bevacizumab plus irinotecan at Rigshospitalet (years 2018-2022) and evaluated with consecutive [18F]FET PET imaging at baseline and after 2 cycles of treatment were included. Metabolic tumor volumes (MTV), maximum tumor-to-background ratios (TBRmax), mean tumor-to-background ratios (TBRmean) and associated changes were determined. Cox regression and receiver operating characteristic analyses were used to identify predictors of survival beyond the median overall survival (OS). A total of 82 patients (median OS 9.3 months, 95% confidence interval: 8.3-10.4) were included. Tumors were smaller and less metabolically active at follow-up. PET RANO showed a 68% response rate and was independently associated with a longer OS (P < .001). Analysis of individual PET parameters identified 3 thresholds that independently predicted longer OS with response rates of 35%-40%: (i) more than 76% reduction in MTV, (ii) more than 21% reduction in TBRmax, and (iii) follow-up MTV under 3.5 cm3. On using [18F]FET PET for response assessment during bevacizumab treatment, the proposed response criteria improved identification of responders when compared with the PET RANO criteria. Nevertheless, further refinement and validation is needed to enhance PET-based response assessment.

PMID 42719446
阅读全文 →
PubMedAdvanced healthcare materials2026-09-10

A Spatially Controlled Glioblastoma-on-a-Chip for Dissecting Tumor-Immune-Vascular Crosstalk and Bevacizumab Resistance.

Wang Zixuan Z, Gao Jie J, Chan Junned J, Fang Yongcong Y et al.

Glioblastoma (GBM) is an aggressive brain malignancy with a median survival of only 15 months despite current therapeutic interventions. A major obstacle to effective treatment is the intricate tumor microenvironment (TME), which drives tumor progression and therapy resistance. However, existing in vitro models lack micrometer-scale spatial control over multiple cellular components and fail to preserve their dynamic interactions, limiting our understanding of tumor biology and treatment responses. Here, we present a spatially controlled GBM-on-a-chip (scGoC) platform that integrates a novel organoid positioning strategy, enabling the reconstruction of the TME within a 3D matrix at micron-level precision. This platform allows real-time monitoring of dynamic tumor-immune-vascular interactions, providing refined insights into tumor progression and drug responses. Using the scGoC, we demonstrate that endothelial cells not only promote microglial migration toward tumor organoids but also drive their polarization toward an immunosuppressive phenotype, faithfully recapitulating hallmark features of GBM progression. Importantly, the platform reveals a pro-tumorigenic adaptive response to bevacizumab monotherapy, driven by the upregulation of HIF-1 signaling and metabolic reprogramming pathways, providing mechanistic insights into GBM treatment. Collectively, the scGoC establishes a versatile and standardized tool for decoding complex cellular communications and investigating mechanisms of treatment response with broad applicability across cancer research.

PMID 42717630
阅读全文 →
PubMedFrontiers in oncology2026-09-10

The unusual first sign of presentation of hepatocellular carcinoma: a rare case report.

Morra Rocco R, Nappi Anna A, Zanaletti Nicoletta N, Piccirillo Mauro M et al.

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, characterized by aggressive biological behavior and a high propensity for extrahepatic spread. The most common sites of metastasis are the lungs, regional lymph nodes, bones, adrenal glands, and peritoneum. In contrast, the paranasal sinuses are an unusual site for metastatic HCC, and involvement of the sphenoid sinus represents an even rarer event. We report the case of a 67-year-old male patient who presented with transient diplopia, left eyelid ptosis, and refractory epistaxis as the initial clinical manifestations of a previously undetected HCC. Histopathological evaluation of the sinus mass and subsequent imaging confirmed a metastatic lesion from a silent primary liver tumor. The patient was managed using a multidisciplinary approach, undergoing radiation therapy to the sphenoid sinus for pain control and endovascular embolization of the sphenopalatine arteries for refractory epistaxis. In March 2026, a contrast-enhanced computed tomography (CT) scan revealed new osteolytic lesions, consistent with bone metastases, involving the proximal third of the left clavicle and the T9 vertebral body. The patient subsequently received further palliative radiotherapy to the left clavicle and T7-T9, and initiated first-line systemic therapy with atezolizumab plus bevacizumab, completing four cycles. Due to disease progression at multiple skeletal sites and in the sphenoid region, as revealed by a CT scan in June 2026, second-line treatment with lenvatinib was initiated and is ongoing at the latest follow-up. Despite its rarity, the differential diagnosis of a paranasal sinus lesion should include the possibility of metastasis from HCC, particularly in patients with underlying chronic liver disease. Histopathological confirmation and a multidisciplinary approach are critical for optimizing therapeutic planning in this challenging clinical scenario.

PMID 42718515
阅读全文 →
PubMedSurgical case reports2026-09-10

Laparoscopic Low Anterior Resection with Ureterectomy and Ileal Ureter Interposition for Ureter-Invading Locally Recurrent Rectal Cancer: A Case Report.

Yamamoto Takumi T, Kitagawa Yusuke Y, Miki Hisanori H, Watanabe Jun J et al.

Locally recurrent rectal cancer (LRRC) with ureteral invasion is surgically demanding because curative-intent resection often requires en bloc ureterectomy, and urinary diversion may be considered. Although ileal interposition for ureteral reconstruction can preserve renal function when direct ureterocystostomy or uretero-ureterostomy is not possible, reports of this procedure for LRRC remain scarce. An 81-year-old man underwent laparoscopic high anterior resection for rectosigmoid adenocarcinoma (pT3N1bM0, pStage IIIB) in March 2020, and adjuvant chemotherapy was not administered because of the patient's preference. Twenty months later, a metachronous liver metastasis was detected and resected by laparoscopic partial hepatectomy. Surveillance imaging in 2023 revealed an approximately 20-mm tumor consistent with recurrence located anterior to the left iliac bifurcation, involving the left ureter at the common iliac crossing and causing hydronephrosis, for which percutaneous nephrostomy was performed for decompression. The tumor was RAS-mutant, BRAF wild-type, and microsatellite stable. FOLFOX plus bevacizumab was selected as a standard systemic treatment option for recurrent colorectal cancer with RAS mutation, but the treatment was discontinued due to toxicity, mainly fatigue. Because the disease remained confined to the pelvis without distant metastasis on PET/CT and first-line chemotherapy became difficult to continue, curative-intent resection was planned. Curative-intent laparoscopic low anterior resection with en bloc ureterectomy was performed. Because tension-free ureterocystostomy or uretero-ureterostomy was considered difficult due to limited tissue mobility, a short-segment isoperistaltic ileal ureter interposition was constructed. Postoperative paralytic ileus resolved conservatively (Clavien-Dindo grade II). The urinary catheter, ureteral stent, and nephrostomy tube were removed on PODs 8, 32, and 49, respectively, without deterioration of renal function. No adjuvant therapy was administered. The patient remained free of clinical and radiological recurrence 12 months after surgery. Laparoscopic salvage resection with en bloc ureterectomy and ileal ureter interposition may be a feasible renal-preserving option for selected patients with ureter-invading LRRC.

PMID 42719033
阅读全文 →
PubMedOxford medical case reports2026-09-09

Selective cTACE to a segment target hepatocellular carcinoma lesion during atezolizumab plus bevacizumab therapy achieving delayed hypovascularization and shrinkage of non-target intrahepatic lesions: a case report.

Hara Hidenobu H, Matsumoto Hiroaki H, Yoshinaga Ami A, Ishii Hikari H et al.

Atezolizumab plus bevacizumab (Atez/Bev) is the standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). We report HCC with intrahepatic progression during Atez/Bev in which selective conventional transarterial chemoembolization (cTACE) to a single lesion was followed by non-target lesion shrinkage. An 82-year-old woman with metabolic dysfunction-associated steatotic liver disease was diagnosed with BCLC stage B hepatocellular carcinoma in segments 5/7. After TACE, residual viable tumor persisted in segment 5, and Atez/Bev was initiated. After 4 cycles, a new intrahepatic lesion appeared in segment 8, and after 7 cycles, lesions in segments 5/7/8 enlarged, meeting the mRECIST progressive disease criteria. Systemic therapy continued, and selective cTACE for the segment 5 lesion was added. At 3 months post-cTACE, segment 5 viability decreased, but overall mRECIST remained progressive disease. At 6 months (November 20XX + 1), arterial enhancement in segment 5 resolved and non-target segment 7/8 lesions became hypovascular and shrank, achieving partial response.

PMID 42713611
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab